Medindia

X

Merrimack Pharmaceuticals and sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 and exemestane in Breast Cancer

Thursday, July 22, 2010 Drug News J E 4
Advertisement
The trial, enrolling patients at multiple centers across the United States, is part of a broad Phase 2 program for MM-121 launched by Merrimack and sanofi-aventis this year

Contact: Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli@merrimackpharma.com;

Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424, betsy@raymondstevenson.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Mylan Announces Settlement Agreement for NamendaŽ
S
Cardiogenesis Corporation to Report 2010 Second Qu...